The last thing millions of cancer cells around the world see are, antibody-drug conjugates (ADC’s) developed by Seattle Genetics. ACD’s treat cancer by specifically targeting cancer cells and ignoring healthy cells. Dr. Clay B. Siegall, co-founder and President of Seattle Genetics, is the sniper all forms of cancer fear most. Patients now have precision guided treatment options available as an alternative to chemotherapy.
Seattle Genetics is the undisputed leader in ACD technology. Major pharmaceutical companies such as GlaxoSmithKline and Pfizer are using Seattle Genetics’ ACD technology to develop more precise cancer treatments. A targeted approach to treatment greatly benefits cancer patients. Traditionally, chemotherapy is the most common treatment they are offered; however, it destroys healthy cells as well. The side effects can be brutal. Seattle Genetics’ ACD technology locks on to cancer cells only. This accuracy improves a patient’s overall quality of life, thanks to Dr. Siegall’s innovation and leadership.
The wide-spread use of ACD technology by pharmaceutical companies, is made possible by licensing agreements. This stroke of genius is the brain child of Dr. Siegall.
Pharmaceutical companies purchase licenses to use the technology in the development of cancer treatment options with reduced side effects. The resulting breakthroughs are too long to list. Furthermore, the licenses have provided over $300 million in revenue for Strategic Genetics over the years. It is a win-win situation. Starting with Dr. Siegall’s ability to maximize the potential of ACD technology, by putting in the hands of the best cancer treatment developers on the planet.
No longer will cancer patients wonder if the treatment they are receiving is causing more harm than good. Dr. Siegall and Seattle Genetics are keeping companies such as Pfizer and GlaxoSmithKline “on target” with ACD’s. Providing patients something they always dreamed of. A growing variety of targeted cancer treatments that afford them a better quality of life…bullseye.
Connect with Clay Siegall: